MADISON, Wis.--(BUSINESS WIRE)--TomoTherapy Incorporated (NASDAQ: TOMO), producer of the Hi·Art® treatment system for advanced radiation therapy, today confirmed receipt of a letter dated November 17, 2008, from Avalon Capital and issued the following statement from TomoTherapy’s Board of Directors:
